Introduction {#s1}
============

Acute respiratory distress syndrome (ARDS) is a clinical syndrome with high morbidity and mortality. ARDS is characterized by severely hypoxemic respiratory failure that requires mechanical ventilation and often induces organ failure. In addition, ARDS results in lower quality of life in patients after hospital discharge ([@B19]; [@B40]; [@B20]).

Mechanistically, ARDS is described as an inflammatory syndrome characterized by inflammatory injuries to the lungs mediated by immune cells, such as neutrophils and macrophages ([@B1]; [@B13]; [@B38]). The inflammatory response in the lungs is not under control and would lead to alveolar and capillary endothelial barrier injury, increasing its permeability to fluid. As the disease progresses, inflammatory factors, such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-6, and IL-12 increase, and inflammatory cells infiltrate the lungs. Moreover, an increase in proteinaceous fluid within the alveolar space leads to complete hypoxemia. Furthermore, widespread coagulation cascade activation causes microvascular thrombosis and fibroproliferation ([@B46]). A previous study showed that albuterol could reduce the number of ventilator-free and organ failure-free days, yet it could not improve ARDS patient survival ([@B47]). At present, despite advancements in our understanding of ARDS pathogenesis, there remains a lack of effective therapy for ARDS ([@B3]; [@B4]).

Previous reports demonstrate that platelets play a substantial role in the onset of ALI or ARDS ([@B52]; [@B29]; [@B50]), as well as in the progression of these diseases ([@B14]; [@B11]; [@B30]). Experimental studies suggest that aspirin could ameliorate neutrophil activation and reduce inflammatory factors, such as TNF-α and IL-1 expression in lung macrophages, and it could also lower the levels of plasma thromboxane and reduce the degree of platelet sequestration in lung tissues ([@B6]; [@B49]). Unfortunately, this effect in clinical patients has been controversial. For instance, a prospective cohort study has shown that preadmission aspirin use was associated with a lower risk of ARDS ([@B7]). However, several other observational cohort studies ([@B25]; [@B35]; [@B44]; [@B5]; [@B32]) and one RCT ([@B26]) have reported contrary results that, compared to non-aspirin use, prior aspirin use could not lower ARDS incidence. Numerous studies have demonstrated an effective therapeutic role of antiplatelet treatment in at-risk patients ([@B25]; [@B12]; [@B7]; [@B5]). A meta-analysis showed that aspirin use prior to the onset of sepsis could improve the mortality of septic patients ([@B33]); however, there is no relevant evidence that shows whether aspirin is associated with lower ARDS risk or hospital mortality in at-risk patients. Therefore, collecting the available data and assessing the collective effects of aspirin on ARDS incidence are necessary to resolve the current controversy.

Materials and Methods {#s2}
=====================

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([**Additional File 1**](#SM1){ref-type="supplementary-material"}) ([@B34]). The protocol of this meta-analysis has been registered in PROSPERO (<http://www.crd.york.ac.uk/PROSPERO>), and the registration number is **CRD42018103854**.

Screening of Relevant Studies {#s2_1}
-----------------------------

A flowchart of the screening procedure for relevant studies is presented in [**Figure 1**](#f1){ref-type="fig"}. We searched all the available data of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science until July 14, 2019. We also searched MeSH/Emtree and title/abstract terms for the combined key words, "acute lung injury", "acute respiratory distress syndrome", "critically ill patients", "aspirin", and "acetylsalicylic acid". The search strategy for relevant studies are detailed in [**Additional File 2**](#SM2){ref-type="supplementary-material"}.

![Flowchart of the study screening process.](fphar-11-00738-g001){#f1}

Inclusion Criteria {#s2_2}
------------------

This article includes the relevant studies to analyze the effects of aspirin on ARDS incidence in at-risk patients if: (1) the studies were observational cohort studies or randomized clinical trials (RCTs); (2) the study\'s participants were at-risk of ARDS or ARDS patients in the original articles; (3) the experimental arms of the studies were aspirin use prior to ARDS onset; (4) the control arms of the studies were at-risk ARDS patients who did not use aspirin or used placebo; (5) the studies measured the risk of ARDS or hospital mortality in at-risk patients that used aspirin and at-risk patients that did not use aspirin; and (6) the studies were published in the English language. The patients included in this meta-analysis were all adults. At-risk patients are defined as patients with the presence of at least one major risk factor for acute lung injury (ALI), including aspiration, pneumonia, sepsis, shock, pancreatitis, high-risk trauma, or high-risk surgery.

Extraction of Data {#s2_3}
------------------

First, two investigators (HoL and YY) extracted the data from the above four databases. In cases where disagreements occurred, the determination of whether the study would be included was discussed with the presence of a third reviewer (HuL). Then, the relevant data, including the first name of the first author in the original studies, the publication date, the represented country of the articles, the design type of the included studies, the number of experimental arms and control arms, the study period, the dose of aspirin used, the ARDS or acute lung injury definition, and the ARDS risk and hospital mortality were extracted from the original reports. Moreover, we evaluated the risk of ARDS as the primary outcome and hospital mortality as the secondary outcome.

Risk of Bias Assessment {#s2_4}
-----------------------

According to the principle of the Cochrane Collaboration ([@B17]), all domains of bias in the RCT mainly included random sequence generation, allocation concealment, the blinding of participants, staff and outcomes assessors, incomplete outcome data, selective outcome reporting, and other biases. Additionally, we used the Newcastle-Ottawa Scale (NOS) to assess the risk of bias in the observational cohort studies ([@B42]), and the items included the cohort selection, the comparability of the cohort design and analysis, as well as the adequacy of outcome measures. The total score was equal to or greater than seven points (high quality, [**Additional File 3**](#SM3){ref-type="supplementary-material"}).

Statistical Analysis {#s2_5}
--------------------

The outcomes in this meta-analysis were the risk of ARDS and the hospital mortality in at-risk patients. In the meta-analysis, the heterogeneity included methodological heterogeneity, clinical heterogeneity, and statistical heterogeneity. Most of the meta-analysis contained statistical heterogeneity, which was evaluated by *I^2^* and *P* values. The degree of variability was due to the heterogeneity, not the sample error ([@B21]; [@B22]), and when *I^2^* was less than 50%, between 51 and 75%, or equal to or greater than 76%, the heterogeneity was considered low, moderate, or high, respectively. Since the heterogeneity was low in ARDS risk and hospital mortality outcomes, we performed a meta-analysis of the fixed effects model using the inverse variance-weighted average method to calculate the pooled odds ratios (ORs) and 95% confidence intervals (CIs) for each patient outcome. To confirm the statistical significance, we performed a two-sided t-test, in which a *P*-value smaller than 0.05 was considered statistically significant. The software Stata 14.0 (College Station, Texas 77845 USA, Serial number: 401406267051) was used for all the statistical analyses in this meta-analysis.

Results {#s3}
=======

Screening of Relevant Studies {#s3_1}
-----------------------------

Based on the combined keywords, a total of 1,470 articles were found in our search of the four databases, 272 of which were duplicate studies. Among the remaining reports, 37 studies were considered potential articles based on their titles and abstracts. In the end, based on the inclusion criteria, seven studies ([@B25]; [@B35]; [@B44]; [@B7]; [@B5]; [@B32]; [@B26]) were confirmed for meta-analysis after full text reading and judgment. The flowchart of the screening strategy for relevant studies is shown in [**Figure 1**](#f1){ref-type="fig"}.

Study Characteristics {#s3_2}
---------------------

A total of seven articles ([@B25]; [@B35]; [@B44]; [@B7]; [@B5]; [@B32]; [@B26]) with 6,764 at-risk patients were included in this study. All patients were considered at risk of ARDS or diagnosed with ARDS. Additionally, the eligible participants in this study were the patients with ARDS/ALI, or with the presence of at least one major risk factor for acute lung injury, including aspiration, pneumonia, sepsis, shock, pancreatitis, high-risk trauma, or high-risk surgery. Moreover, the outcomes were the risk of ARDS/ALI and hospital mortality, and the data extracted from all eligible articles were the risk adjusted OR and 95% CI. In case the OR and its 95% CI were not reported, it was computed using related data reported in the original articles. Moreover, the first name of the first author in the original studies, the publication date, the represented country of the articles, the design type of the included studies, the number of the experimental arms and control arms, the study period, the dose and duration of aspirin use, and the ARDS or acute lung injury definition were also extracted. Further details of the study populations and interventions are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of the included studies.

  Author (year)   Country       S     P    I                        C                                                      O                                       Quality score                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  --------------- ------------- ----- ---- ------------------------ ------------------------------------------------------ --------------------------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- --------------------------------------------------------------------------------------------------------------- ---
  [@B5]           UK            PS    SC   Dec-10--07/2012          ARDS patients                                          The North American-European consensus   75--300 mg/daily                                  Age, APACHE II score, Coronary artery disease, PaO~2~ /FiO~2~ ratio, Vasopressor use                                                                                                                                                                                             56/146     ICU mortality; duration of ICU stay; hospital mortality.                                                        7
  [@B7]           China         PS    SC   23/01/2006--18/02/2012   Critically ill patients                                Berlin definition                       81 mg/d, 325 mg/d                                 Age, gender, race, sepsis and APACHE II score                                                                                                                                                                                                                                    287/862    Risk of ARDS; risk of sepsis.                                                                                   8
  [@B25]          US            PS    MC   Mar-09--09/2009          Patients with at least one major risk factor for ALI   Standard American-European consensus    NA                                                Age, Sex (male), Admission Source, Diabetes Mellitus, Cirrhosis, Chronic Kidney Disease, Stage V, Congestive Heart Failure, Class IV, Chronic Obstructive Pulmonary Disease, Gastroesophageal Reflux Disease, Immunosuppression, ACE-I/ARB, Statin, Amiodarone                   976/2879   Development of ARDS; ICU and hospital mortality; ICU and hospital length of stay.                               7
  [@B32]          US            RS    SC   1/7/2008--30/06/2013     Patients who had AVRS during a 5-year period           Berlin definition                       81 mg/d during the study period                   Age, Cerebral vascular disease, Congestive heart failure, Diabetes mellitus, Dyslipidemia, Dialysis dependent, Male sex, Height, Hypertension, Infectious endocarditis, International normalized ratio, Left ventricular ejection fraction, Peripheral vascular disease, Weigh   181/194    Occurrence of ARDS; nadir PaO~2~ /FiO~2~ ratio                                                                  7
  [@B35]          UK            PS    SC   23/01/2006--01/04/2008   Critically ill patients                                The North American-European consensus   81 mg or 365 mg daily use                         Prehospital statin use, Age, Gender, Current Tobacco Use, Race, APACHE II score                                                                                                                                                                                                  149/462    ICU mortality; duration of ICU stay; hospital mortality                                                         7
  [@B26]          US            RCT   MC   02/07/2012--17/11/2014   Patients with LIPS ≥ 4                                 Berlin definition                       325 mg loading dose followed by 81 mg/d for 7 d   NA                                                                                                                                                                                                                                                                               195/195    Development of ARDS; ventilator-free days to hospital 28 d; ICU and hospital lengths of stay; 28 d mortality.   7
  [@B44]          Netherlands   PS    SC   NA                       Critically ill patients                                2004 consensus definition               80 mg/d or 100 mg/d for 30 d                      Amount of RBCs, FFP, PLTs and propensity score                                                                                                                                                                                                                                   109/109    Incidence of transfusion-related ALI                                                                            8

United Kingdom; US, United States; PS, prospective study; RS, retrospective study; RCT, randomized clinical trial; SC, single center; MC, multicenter; ICU, intensive care unit; ARDS, acute respiratory distress syndrome; ALI, acute lung injury; LIPS, lung injury prediction score; AVRS, aortic valve replacement surgery; NA, not applicable.

Assessing the Risk of Bias {#s3_3}
--------------------------

Six of the included articles ([@B25]; [@B35]; [@B44]; [@B7]; [@B5]; [@B32]; [@B26]) were observational cohorts and one was an RCT ([@B26]), all of which had the risk of bias scores equal to or greater than seven points, suggesting a low risk of bias ([**Table 1**](#T1){ref-type="table"} and [**Additional File 3**](#SM3){ref-type="supplementary-material"}).

Effects of Aspirin on Patient Outcomes {#s3_4}
--------------------------------------

In the seven eligible studies ([@B25]; [@B35]; [@B44]; [@B7]; [@B5]; [@B32]; [@B26]), the risk of ARDS was chosen as the primary outcome (6,764 patients). Prior aspirin use was significantly associated with a decreased risk of ARDS in at-risk patients (OR, 0.78; 95% CI, 0.64--0.96; *P* = 0.018; *I* ^2^ = 1.7%; [**Figure 2**](#f2){ref-type="fig"}). Hospital mortality was treated as the secondary outcome, and the difference between prior aspirin use and non-aspirin use for hospital mortality in at-risk patients was not significant (OR, 0.88; 95% CI, 0.73--1.07; *P* = 0.204; *I* ^2^ = 0%; [**Figure 3**](#f3){ref-type="fig"}).

![Forest plot showing the association between prior aspirin use and ARDS incidence in at-risk patients. The synthetic odds ratios (ORs) of the included studies indicate that prior aspirin use could decrease the incidence of ARDS in at-risk patients based on the fixed effects model.](fphar-11-00738-g002){#f2}

![Forest plot showing the association between prior aspirin use and hospital mortality in at-risk patients. The pooled odds ratios (ORs) of the included studies indicate that prior aspirin use cannot decrease hospital mortality in at-risk patients, according to the fixed effects model.](fphar-11-00738-g003){#f3}

Sensitivity Analysis {#s3_5}
--------------------

Since all of the included studies were observational studies or an RCT with a low risk of bias ([**Table 1**](#T1){ref-type="table"}), the sensitivity analysis was not conducted on the meta-analysis, according to the methodological criteria. Instead, the analysis was used to evaluate the effect of each study on the collective OR and 95% CI by omitting articles one at a time. Our data suggested that the results were robust and reliable ([**Figure 4**](#f4){ref-type="fig"} and [**Supplemental Figure 1**](#SM1){ref-type="supplementary-material"}).

![Sensitivity analysis indicating that the included studies were conclusive and reliable regarding the use of aspirin and the risk of ARDS in at-risk patients.](fphar-11-00738-g004){#f4}

Publication Bias {#s3_6}
----------------

A funnel plot revealed that no asymmetry was found upon visual inspection ([**Figure 5**](#f5){ref-type="fig"} and [**Supplemental Figure 2**](#SM1){ref-type="supplementary-material"}). The Egger linear regression test showed that there was no potential publication bias (*P* = 0.600 and 0.544; [**Figure 6**](#f6){ref-type="fig"} and [**Supplemental Figure 2 and 3**](#SM1){ref-type="supplementary-material"}, respectively).

![Funnel plot assessing the risk of ARDS after prior aspirin use in at-risk patients.](fphar-11-00738-g005){#f5}

![Egger regression line evaluating the publication bias of the included studies.](fphar-11-00738-g006){#f6}

Discussion {#s4}
==========

This article includes seven studies with 6,764 patients. Our meta-analysis demonstrates that prior aspirin use could improve the risk of ARDS incidence, but may not decrease hospital mortality in at-risk patients. To the best of our knowledge, this is the first time that systematic evidence was found for describing the effect of prior aspirin use on ARDS risk and hospital mortality in at-risk patients. However, further clinical studies are necessary to explore whether aspirin is efficacious in the hospital in at-risk patients previously untreated by aspirin.

[@B27] first reported that aspirin could decrease the intrapulmonary shunt in pig ALI model by decreasing the prostacyclin level or increasing leukotriene level. Subsequently, [@B51] demonstrated that an important feature of ARDS is platelet neutrophil aggregation, and aspirin could reduce the platelet neutrophil aggregation and increase the gas exchange, thereby decreasing the mortality of ARDS animal model. However, the [@B15] showed that aspirin treatment could increase the neutrophil number in the bronchial alveolar fluid in the ALI mouse model. Interestingly, a systematic review ([@B36]) showed that aspirin could attenuate inflammation and pulmonary edema and improve the survival of preclinical ARDS models. These preclinical experiments provided evidence for the use of aspirin in future clinical studies. A randomized clinical trial ([@B26]) reported that aspirin did not reduce the incidence of ARDS, which do not support continuation to a larger clinical trial, which was inconsistent with the conclusion of our meta-analysis. Importantly, a subsequent prospective human trial ([@B18]) indicated that aspirin can inhibit pulmonary neutrophilic inflammation, at both low and high doses, which was agreed with the potential effect of aspirin treatment for ARDS in our study, and the further clinical studies should be required and evaluate the aspirin for the prevention and treatment of ARDS.

Several mechanisms underlying the effect of aspirin on improving the risk of ARDS in at-risk patients have been elucidated. Numerous studies have shown that immune cells, especially macrophages and neutrophils, migrate to and activate in the lung endothelium, possibly inducing alveolar-capillary membrane injury ([@B24]; [@B39]). Furthermore, studies indicate that inflammatory factors could activate platelets, change platelet granule secretion and platelet shape that regulate immune function and the inflammatory response, and subsequently promote the onset and progression of ARDS ([@B43]; [@B50]; [@B48]). Mechanistically, aspirin is an antiplatelet drug that may exert anti-inflammatory functions, such as decreasing nuclear factor κB and intracellular adhesion molecule-1 expression. Interestingly, aspirin can also reduce levels of the platelet, p-selectin ([@B16]; [@B37]; [@B45]; [@B10]). Moreover, studies also attest to the ability of aspirin to inhibit thromboxane A2 production by acetylating cyclooxygenase-1, thereby ameliorating aggregation of neutrophils within the lung ([@B29]; [@B16]). Furthermore, a review reported that aspirin acetylates cyclooxygenase-1, which inhibits its activity and thereby restrains the expression of prostaglandin and leukotriene, resulting in the alleviation of the inflammatory response ([@B2]). Aspirin was also confirmed to protect endothelial cells from activated platelets and to subsequently reduce the number of inflammatory cells as well as the levels of inflammatory factors and adhesion molecules ([@B31]). Furthermore, several studies have revealed that aspirin could improve the pulmonary barrier and lung injury by promoting the resolution of lipoxins, leading to pivotal anti-inflammatory responses and pro-resolution bioactions ([@B9]; [@B8]; [@B23]). A growing body of evidence shows that aspirin functions to decrease the intrapulmonary shunt, protect from pulmonary hypertension, and ameliorate lung edema and inflammation, thereby decreasing the risk of ARDS ([@B41]; [@B28]).

Our meta-analysis used a synthetic statistical analysis of the available data to provide systematic evidence to resolve the aforementioned controversy regarding the aspirin use in the clinic. A meta-analysis is considered to be statistically heterogeneous when the difference of the outcomes in each study is beyond what is expected. In this meta-analysis, the pooled effect of whether ARDS risk or hospital mortality showed a low degree of heterogeneity reflected that the included studies exhibited no differences.

This article is advantageous in a number of ways. First, the results of the original studies were adjusted for confounding factors, which means the pure effect of prior aspirin use on ARDS risk and hospital mortality was obtained. Second, the sample size from each study was relatively large to ensure the sample is representative to produce robust results. Third, one RCT was enrolled in this meta-analysis, demonstrating the high quality of the original articles and making our study more conclusive and reliable. Fourth, the risk of bias assessment indicated a low risk of bias in all the included studies. Fifth, a fixed-effect model with generic inverse variance was performed, and the adjusted ORs and 95% CIs were extracted, so that the collective outcome of the ORs for the effect of aspirin on ARDS risk and hospital mortality could be calculated. Finally, the sensitivity analysis revealed that the results of this study were conclusive and reliable.

This meta-analysis also has several limitations. We studied the association between prior aspirin use and ARDS risk or hospital mortality in at-risk patients; however, only one RCT investigated such an association, and how long one should take aspirin to prevent ARDS ideally has not been determined. Further clinical studies are necessary to explore whether aspirin is efficacious in the hospital in at-risk patients previously untreated by aspirin. Although at-risk patients may benefit from prior aspirin use, the effects, safety, and dose of aspirin administration, initiation, and continuation in patients who are at risk of ARDS still require exploration.

Conclusions {#s5}
===========

This is the first article to elucidate the efficacy of prior aspirin use on ARDS risk and hospital mortality in at-risk patients. Our results indicate that, in at-risk patients, prior aspirin use is associated with a decreased risk of ARDS, but prior aspirin use and hospital mortality are not significantly associated. However, the results presented in this article should be further confirmed by clinical studies.
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Egger regression line evaluating the publication bias of the hospital mortality of ARDS after prior aspirin use in at-risk patients in the included studies.
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